Journal of Medical Systems
Barriers, limitations, and challenges to the implementation of artificial intelligence in Latin American healthcare systems: a scoping review
Valentina Velasco-Muñoz, Pablo Pineda-Sanabria, Juan Diego Navarro-Sánchez, Daniela Varón-Jauregui, Lucas Gallego-Tristancho, Mateo Uribe-Gaviria, Santiago Andrés Suárez-Gómez, Luis M. Ahumada
Corresponding author: Valentina Velasco-Muñoz, Department of Internal Medicine, Pontificia Universidad Javeriana, Cra 7 No 40 - 62 , Bogotá D.C., Colombia. Email: velascomv@javeriana.edu.co; telephone: +57-315-632-0743.

Online Resource 1: PRISMA-ScR Checklist

Completed for the manuscript "Barriers, limitations, and challenges to the implementation of artificial intelligence in Latin American healthcare systems: a scoping review" (J Med Syst submission draft, 21 August 2026).

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED IN (SECTION)
TITLE			
Title	1	Identify the report as a scoping review.	Title ("… a scoping review")
ABSTRACT			
Structured summary	2	Structured summary: background, objectives, eligibility criteria, sources of evidence, charting methods, results, conclusions.	Abstract (Background; Objective; Methods; Results; Conclusions)
INTRODUCTION			
Rationale	3	Rationale in the context of what is already known; why a scoping-review approach.	Rationale (paragraphs 1–4)
Objectives	4	Explicit statement of the questions and objectives, referencing the PCC (Population, Concept, Context) or other approach.	Rationale, final paragraph; PCC framework in Methods, "Eligibility criteria"
METHODS			
Protocol and registration	5	Indicate whether a review protocol exists; state if and where it can be accessed (e.g., URL) and, if available, provide registration information including registration number.	Methods, opening paragraph: OSF registration https://osf.io/6byqz (registered 29 May 2026); the three post-registration departures (evidence-rule revision; PubMed export correction; recharting after editorial review) are disclosed there and in Statements and Declarations, "Registration"
Eligibility criteria	6	Specify characteristics of the sources of evidence used as eligibility criteria (e.g., years considered, language, publication status), and provide a rationale.	Methods, "Eligibility criteria" (PCC; 2016–2026; English, Spanish, Portuguese; rationale stated)
Information sources	7	Describe all information sources in the search (e.g., databases with dates of coverage and contact with authors to identify additional sources), as well as the date the most recent search was executed.	Methods, "Information sources and search" (5 databases: PubMed/MEDLINE, Scopus, Web of Science, Embase, LILACS; searched 3 June 2026; PubMed re-executed 3

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED IN (SECTION)
			September 2026 with an entry-date cap at 3 June 2026)
Search	8	Present the full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	Methods, "Information sources and search" (full PubMed string as executed, including the entry-date cap); Online Resource 2 (all five databases)
Selection of sources of evidence	9	State the process for selecting sources of evidence (i.e., screening and eligibility) included in the scoping review.	Methods, "Selection, charting, and verification" (duplicate screening at title/abstract and full text, third-reviewer adjudication; screening decisions carried forward for records present in the corrected PubMed export); Online Resource 3 (full-text exclusions with reasons, and the five reports sought but not retrieved)
Data charting process	10	Describe the methods of charting data from the included sources of evidence (e.g., calibrated forms tested by the team) and any processes for obtaining and confirming data from investigators.	Methods, "Selection, charting, and verification" (first-round piloted form; full recharting under a coding manual frozen before recharting, v1.10, Online Resource 4; quotation gated mechanically; verification in full by one reviewer, review in full by a second, count matrices audited by a third)
Data items	11	List and define all variables for which data were sought and any assumptions and simplifications made.	Methods, "Selection, charting, and verification" (level of analysis, thematic domain, sub-theme, AI-specific or digital infrastructure, claim provenance, experienced or anticipated, evidence type; source-level design group and regional specificity); definitions in Online Resource 4
Critical appraisal of individual sources of evidence	12	If done, provide a rationale for conducting a critical appraisal of included sources of evidence; describe the methods used and how this information was used in any data synthesis (if appropriate).	Methods, "Selection, charting, and verification", final paragraph: not undertaken; scoping-review rationale stated, and quality did not affect eligibility
Synthesis of results	13	Describe the methods of handling and summarizing the data that were charted.	Methods, "Synthesis" (level-of-analysis by domain framework; instance-level and study-level denominators; stratification by design group and evidence type; three sensitivity analyses);

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED IN (SECTION)
			Methods, "Selection, charting, and verification" (counting rule)
RESULTS			
Selection of sources of evidence	14	Give numbers of sources of evidence screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally using a flow diagram.	Results, "Selection of sources" (2,742 records; 787 duplicates removed; 1,955 screened; 104 sought; 5 not retrieved; 99 assessed; 56 excluded with reasons; 43 included; 1,031 distinct barrier instances); Figure 1
Characteristics of sources of evidence	15	For each source of evidence, present characteristics for which data were charted and provide the citations.	Results, "Characteristics of the included studies"; Table 1 (all 43 sources, with design group, barrier instance count, predominant domains and regional specificity); Figure 2
Critical appraisal within sources of evidence	16	If done, present data on critical appraisal of included sources of evidence (see item 12).	Not applicable (see item 12)
Results of individual sources of evidence	17	For each included source of evidence, present the relevant data that were charted that relate to the review questions and objectives.	Table 1; Results, "Barriers by level of analysis"; Online Resource 5 (every sub-theme with instance and study-level denominators); Online Resource 6 (per-source evidence profile)
Synthesis of results	18	Summarize and/or present the charting results as they relate to the review questions and objectives.	Results, "The barrier map", "Evidence basis of the barriers" (study level, by design group, Table 2; instance level, Figure 4; by sub-theme; AI-specific and regional-specificity sensitivity); Figures 3 and 4; Online Resources 5 and 6
DISCUSSION			
Summary of evidence	19	Summarize the main results (including an overview of concepts, themes, and types of evidence available), link to the review questions and objectives, and consider the relevance to key groups.	Critical synthesis (opening paragraphs)
Limitations	20	Discuss the limitations of the scoping review process.	Limitations (scope and language; conference proceedings; concept boundary; instance counts and the study-level denominators; recharting not blind to the first-round result; post hoc coding of

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED IN (SECTION)
			regional specificity; comparison caveats)
Conclusions	21	Provide a general interpretation of the results with respect to the review questions and objectives, as well as potential implications and/or next steps.	Implications for research, policy and practice; Conclusion
FUNDING			
Funding	22	Describe sources of funding for the included sources of evidence, as well as sources of funding for the scoping review. Describe the role of the funders of the scoping review.	Statements and Declarations, "Funding": the review received no specific funding from any agency in the public, commercial, or not-for-profit sectors, and no funder had a role. Funding of the included sources of evidence was not charted

Source: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018;169:467–73. doi:10.7326/M18-0850.